News | June 04, 2024
Aurigene Pharmaceutical opens biologics facility in Genome Valley, Hyderabad
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Subscribe To Our Newsletter & Stay Updated
